|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ochiai T, Ikoma H, Okamoto K, Kokuba Y,
Sonoyama T and Otsuji E: Clinicopathologic features and risk
factors for extrahepatic recurrences of hepatocellular carcinoma
after curative resection. World J Surg. 36:136–143. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang Y, Nagano H, Ota H, Morimoto O,
Nakamura M, Wada H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A,
et al: Patterns and clinicopathologic features of extrahepatic
recurrence of hepatocellular carcinoma after curative resection.
Surgery. 141:196–202. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gauthier A and Ho M: Role of sorafenib in
the treatment of advanced hepatocellular carcinoma: An update.
Hepatol Res. 43:147–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al:
Regorafenib for patients with hepatocellular carcinoma who
progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bailey CC, Zhong G, Huang IC and Farzan M:
IFITM-family proteins: The cells first line of antiviral defense.
Annu Rev Virol. 1:261–283. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bailey CC, Kondur HR, Huang IC and Farzan
M: Interferon-induced transmembrane protein 3 is a type II
transmembrane protein. J Biol Chem. 288:32184–32193. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feeley EM, Sims JS, John SP, Chin CR,
Pertel T, Chen LM, Gaiha GD, Ryan BJ, Donis RO, Elledge SJ and
Brass AL: IFITM3 inhibits influenza a virus infection by preventing
cytosolic entry. PLoS Pathog. 7:e10023372011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li D, Peng Z, Tang H, Wei P, Kong X, Yan
D, Huang F, Li Q, Le X, Li Q and Xie K: KLF4-mediated negative
regulation of IFITM3 expression plays a critical role in colon
cancer pathogenesis. Clin Cancer Res. 17:3558–3568. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andreu P, Colnot S, Godard C, Laurent-Puig
P, Lamarque D, Kahn A, Perret C and Romagnolo B: Identification of
the IFITM family as a new molecular marker in human colorectal
tumors. Cancer Res. 66:1949–1955. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bing Z, Wang H, Gang Z and Ping L: The
role of IFITM3 in the growth and migration of human glioma cells.
BMC Neurol. 13:2102013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Place RF, Li LC, Pookot D, Noonan EJ and
Dahiya R: MicroRNA-373 induces expression of genes with
complementary promoter sequences. Proc Natl Acad Sci USA.
105:1608–1613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kota J, Chivukula RR, ODonnell KA, Wentzel
EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M,
Clark KR, et al: Therapeutic microRNA delivery suppresses
tumorigenesis in a murine liver cancer model. Cell. 137:1005–1017.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fang Y, Xue JL, Shen Q, Chen J and Tian L:
MicroRNA-7 inhibits tumor growth and metastasis by targeting the
phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.
Hepatology. 55:1852–1862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y and
Zheng X: miR-34a inhibits migration and invasion by down-regulation
of c-Met expression in human hepatocellular carcinoma cells. Cancer
Lett. 275:44–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wong CC, Wong CM, Tung EK, Au SL, Lee JM,
Poon RT, Man K and Ng IO: The microRNA miR-139 suppresses
metastasis and progression of hepatocellular carcinoma by
down-regulating Rho-kinase 2. Gastroenterology. 140:322–331. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu XC, Dong QZ, Zhang XF, Deng B, Jia HL,
Ye QH, Qin LX and Wu XZ: microRNA-29a suppresses cell proliferation
by targeting SPARC in hepatocellular carcinoma. Int J Mol Med.
30:1321–1326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mahati S, Xiao L, Yang Y, Mao R and Bao Y:
miR-29a suppresses growth and migration of hepatocellular carcinoma
by regulating CLDN1. Biochem Biophys Res Commun. 486:732–737. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kogure T, Kondo Y, Kakazu E, Ninomiya M,
Kimura O and Shimosegawa T: Involvement of miRNA-29a in epigenetic
regulation of transforming growth factor-beta-induced
epithelial-mesenchymal transition in hepatocellular carcinoma.
Hepatol Res. 44:907–919. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cho HJ, Kim SS, Nam JS, Kim JK, Lee JH,
Kim B, Wang HJ, Kim BW, Lee JD, Kang DY, et al: Low levels of
circulating microRNA-26a/29a as poor prognostic markers in patients
with hepatocellular carcinoma who underwent curative treatment.
Clin Res Hepatol Gastroenterol. 41:181–189. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu W, Liang B, Liu H, Huang Y, Yin X,
Zhou F, Yu X, Feng Q, Li E, Zou Z and Wu L: Overexpression of
nonSMC condensin I complex subunit G serves as a promising
prognostic marker and therapeutic target for hepatocellular
carcinoma. Int J Mol Med. 40:731–738. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li C, Miao R, Liu S, Wan Y, Zhang S, Deng
Y, Bi J, Qu K, Zhang J and Liu C: Down-regulation of miR-146b-5p by
long noncoding RNA MALAT1 in hepatocellular carcinoma promotes
cancer growth and metastasis. Oncotarget. 8:28683–28695.
2017.PubMed/NCBI
|
|
27
|
Yuan R, Wang K, Hu J, Yan C, Li M, Yu X,
Liu X, Lei J, Guo W, Wu L, et al: Ubiquitin-like protein FAT10
promotes the invasion and metastasis of hepatocellular carcinoma by
modifying beta-catenin degradation. Cancer Res. 74:5287–5300. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fabbri M, Calore F, Paone A, Galli R and
Calin GA: Epigenetic regulation of miRNAs in cancer. Adv Exp Med
Biol. 754:137–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu G, Chen X, Chen S, Ye W, Hou K and
Liang M: miR-19a, miR-122 and miR-223 are differentially regulated
by hepatitis B virus X protein and involve in cell proliferation in
hepatoma cells. J Transl Med. 14:1222016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lewin AR, Reid LE, McMahon M, Stark GR and
Kerr IM: Molecular analysis of a human interferon-inducible gene
family. Eur J Biochem. 199:417–423. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu J, Wang S, Zhao Y, Guo Q, Zhang D, Chen
J, Li J, Fei Q and Sun Y: Mechanism and biological significance of
the overexpression of IFITM3 in gastric cancer. Oncol Rep.
32:2648–2656. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jia Y, Zhang M, Jiang W, Zhang Z, Huang S
and Wang Z: Overexpression of IFITM3 predicts the high risk of
lymphatic metastatic recurrence in pN0 esophageal squamous cell
carcinoma after Ivor-Lewis esophagectomy. PeerJ. 3:e13552015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang M, Gao H, Chen P, Jia J and Wu S:
Knockdown of interferon-induced transmembrane protein 3 expression
suppresses breast cancer cell growth and colony formation and
affects the cell cycle. Oncol Rep. 30:171–178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Meister G: miRNAs get an early start on
translational silencing. Cell. 131:25–28. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chianchiano P, Pezhouh MK, Kim A, Luchini
C, Cameron A, Weiss MJ, He J, Voltaggio L, Oshima K, Anders RA and
Wood LD: Distinction of intrahepatic metastasis from multicentric
carcinogenesis in multifocal hepatocellular carcinoma using
molecular alterations. Hum Pathol. 72:127–134. 2018. View Article : Google Scholar : PubMed/NCBI
|
